Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

Gilead Sciences, a Bay Area-headquartered biotech and pharmaceutical company, is laying off 104 workers in Foster City, with ...

Gilead Sciences Inc (NASDAQ:GILD) stock is trading higher on Thursday after the company reported better-than-expected ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another ... IBD's ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

Despite this setback, Gilead Sciences Inc remains a formidable player in the pharmaceutical industry, with a strong portfolio ...